Loading
Life sciences · Review
Frontiers in Oncology · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objective This meta-analysis investigated the effect of virtual reality–assisted relaxation therapy (VR-ART) on the reduction of psychological symptoms and fatigue in breast cancer survivors. Methods This review followed PRISMA 2020 reporting guidelines. We searched 9 bibliographic databases, plus ClinicalTrials.gov, WHO ICTRP, and GreyGuide, for records published from database inception through September 2026, limited to Chinese- and English-language publications. Backward and forward citation chasing of included studies and related reviews was completed via Web of Science to identify additional eligible records. Parallel-group RCTs evaluating VR-assisted relaxation therapy on psychological symptoms (anxiety, depression, psychological distress) and cancer-related fatigue among breast cancer survivors were included. Two reviewers independently assessed trial risk of bias using the Cochrane RoB 2 tool. Results Ten RCTs with 995 breast cancer survivors were included. Pooled estimates showed VR-ART yielded statistically significant reductions in anxiety (SMD = −1.94, 95% CI [−2.49, −1.40]; P < 0.001), depressive symptoms (SMD = −1.11, 95% CI [−1.36, −0.87]; P < 0.001), and psychological distress (MD = −1.33, 95% CI [−1.99, −0.67]; P = 0.005) versus controls. effect sizes varied across treatment stages; heterogeneity for anxiety and psychological distress disappeared among trials in active treatment stages; heterogeneity for anxiety and psychological distress disappeared among trials in active treatment stages (anxiety: P = 0.91, I² = 0%; psychological distress: P = 0.79, I² = 0%). Combining sensitivity analysis and existing research, we hypothesized that the combination of chemotherapy regimen and VR interactivity might be associated with variability in effect sizes for psychological distress (P = 0.96, I² = 0%); this observation was exploratory and hypothesis-generating only. Fatigue was synthesized qualitatively rather than pooled quantitatively due to high heterogeneity, with studies reporting reduced self-reported fatigue. Conclusion VR-ART was associated with statistically significant reductions in anxiety, depression, psychological distress, and cancer-related fatigue among breast cancer survivors. Based on findings from exploratory subgroup analyses, we speculated that intervention timing, VR interactivity, and concurrent chemotherapy status might influence the magnitude of intervention effects. Formal testing remains absent, and further research is required to develop individualized intervention strategies and optimize treatment responses. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251114925.